Tranberg, Mette https://orcid.org/0000-0002-6285-6694
Van Keer, Severien
Hesselink, Albertus T.
Nørgaard, Pia
Brøndum, Rikke
Wu, Chunsen
Gustafson, Line Winther
Hammer, Anne
Bor, Pinar
Binderup, Karen Omann
Blach, Christina
Vorsters, Alex
Steenbergen, Renske
Funding for this research was provided by:
Independence Research Fund Denmark (1057-00018b)
Danish Cancer Society Research Center (R351-A20092)
Article History
Received: 1 December 2025
Accepted: 26 March 2026
First Online: 10 April 2026
Declarations
:
: The project was listed in the record of processing activities for research projects in the Central Denmark Region (j.no. 1-16-02-313-21) and approved by the Ethics Committee in the Central Denmark Region (j. no: 1-10-72-246-21). All participants provided written informed consent.
: Not applicable.
: Seegene sponsors the Allplex HR HPV assays for the study. According to the contract between Seegene and the University Research Clinic for Cancer Screening and Dept. of Pathology, Randers Regional Hospital, Seegene had no influence on the scientific process and no editorial rights pertaining to this manuscript. The authors retained the right to submit the manuscript. MT have participated in other studies with HPV test kits sponsored by Roche. MT has received honoraria fee from Roche Diagnostics and AstraZeneca for lectures on HPV self-sampling and HPV triage-methods, respectively. SVK is supported by a senior postdoctoral fellowship of the Research Foundation – Flanders (grant no: 12AHX26N). LWG and AH: Have outside this project, received free-of-charge test kits from Roche Diagnostics and AH has received honoraria fee from Exeltis. PN, RB, PB, KOB, and CB: No competing interests. ATH is an employee of Self-screen BV. AV is co-founder of and former board member of Novosanis (Subsidiary of OraSure Technologies Inc, Wijnegem, Belgium), a spin-off company of the University of Antwerp, and was minority shareholder until January 2019. RS is a minority shareholder of Self-screen BV and received consultancy fees form AstraZeneca paid to her institution.